Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04924075
Other study ID # 6482-015
Secondary ID MK-6482-015PT297
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 12, 2021
Est. completion date February 26, 2027

Study information

Verified date June 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Email Trialsites@merck.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).


Recruitment information / eligibility

Status Recruiting
Enrollment 322
Est. completion date February 26, 2027
Est. primary completion date February 26, 2027
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: Cohort A1: Pheochromocytoma/Paraganglioma (PPGL) - Has documented histopathological diagnosis (local report) of pheochromocytoma or paraganglioma Note: Participants are allowed to receive therapy in first line where a satisfactory treatment option does not exist and if participants are not candidates for systemic chemotherapy or have refused such therapy. There is no limit on number of prior systemic therapies. Locoregional therapies or adjuvant/neoadjuvant therapies are not considered a line of prior systemic therapy - Has locally advanced or metastatic disease that is not amenable to surgery or curative intent treatment - Has adequately controlled blood pressure defined as blood pressure =150/90 mm Hg (=135/85 mm Hg for adolescents) and with no change in antihypertensive medications (for participants with concomitant hypertension) for at least 2 weeks prior to start of study treatment. Cohort A2: Pancreatic Neuroendocrine Tumor (pNET) - Has documented histopathological or cytopathological diagnosis (local report) of well-differentiated, low, or intermediate grade (G1 or G2 pNET per 2017 World Health Organization (WHO) classification and grading) pNET. - Has locally advanced disease or metastatic disease that is: 1. Not amenable for surgery, radiation, locoregional therapies or combination modality of such treatments with curative intent. 2. Experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus or sunitinib. Participants who have received >3 prior systemic therapies will be capped to =20% of the cohort. Note: Chemoembolization/radiofrequency ablation/locoregional therapies, neoadjuvant/adjuvant treatments, or somatostatin analog monotherapy or interferon monotherapy will not count as 1 line of prior systemic therapy. Cohorts A1, A2 and PPGL/pNET participants from Cohort D - Has disease progression within the past 12 months from Screening. - Has measurable disease per RECIST 1.1 by computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by local site investigator/radiology assessment and verified by BICR. 1. Irradiated lesions or lesions treated with locoregional therapies should not be used as target lesions unless they clearly demonstrate growth since completion of radiation. 2. Metastatic lesions situated in the brain are not considered measurable and should be considered nontarget lesions. 3. Only lesions of the primary indication for the cohort may be evaluated for measurability; other neoplastic lesions will be documented by the investigator and this information provided to the independent reviewers to ensure that such lesions are not included in the RECIST assessment. 4. Participants who are adolescents (12-17 years of age) need to have a body weight of 40 kilograms (kg) or more. Cohort B1: von Hippel-Lindau (VHL) Disease-Associated Tumors - Have a diagnosis of VHL disease as determined by a germline test (documented germline VHL gene alteration) locally and/or clinical diagnosis. - Have at least 1 measurable PPGL or pNET per RECIST 1.1 by CT or MRI as assessed by local site investigator/radiology assessment and verified by BICR. - Participants from China or Japan defined as participants of Chinese or Japanese origin residing in mainland China or Japan respectively at the time of Screening, must have at least 1 measurable RCC or PPGL or pNET per RECIST 1.1 as assessed by local site investigator/radiology assessment and verified by BICR. - Must be =18 years of age. For Cohort B1 participants with PPGL - Must not have pheochromocytoma >5 cm or paraganglioma >4 cm that requires immediate surgery. - Have adequately controlled blood pressure defined as blood pressure =150/90 mm Hg and with no change in antihypertensive medications (for participants with concomitant hypertension) for at least 2 weeks prior to start of study treatment. - Must not have Metastatic or locally advanced, unresectable PPGL. - Presence of concomitant VHL disease-associated tumors is permitted as long as they do not require immediate surgery or intervention. For Cohort B1 participants with pNET: - Must not have lesion(s) located in the head of the pancreas must be >2 cm that requires immediate surgery. - Must not have lesion(s) located in the body or tail of the pancreas must be >3 cm that requires immediate surgery. - Must not have locally advanced, unresectable or metastatic pNET. - Presence of concomitant VHL disease-associated tumors is permitted as long as they do not require immediate surgery or intervention. For Cohort B1 participants with renal cell carcinoma (RCC): - Must not have lesion(s) >3 cm that requires immediate surgery. - Must not have metastatic RCC. - Presence of concomitant VHL disease-associated tumors is permitted as long as they do not require immediate surgery or intervention. For Cohort C participants with GIST (wt): - Has documented histopathological diagnosis of GIST. - Local test report documenting the absence of sensitizing mutations in both platelet derived growth factor receptor alpha (PDGFRA) and receptor tyrosine kinase (c-KIT). - Has locally advanced or metastatic disease that is not amenable to surgery or curative intent treatment. For Cohort D participants with advanced solid tumors with HIF-2a related genetic alterations: - Local test report documenting germline or somatic mutations in at least one of the HIF-2a related genes. - Has locally advanced or metastatic solid tumor that is not amenable to surgery or curative intent treatment. - Has progressed on/after standard therapy for advanced/metastatic disease. - Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of study intervention: 1. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR 2. Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below: i. Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman/women of childbearing potential (WOCBP) who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. - A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1. Is not a WOCBP OR 2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), for at least 30 days after the last dose of study intervention. - Submit an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (not previously irradiated). Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue if the lesion is accessible and a biopsy is not clinically contraindicated. Note: If participant has only 1 measurable lesion per RECIST 1.1, the biopsy specimen should be obtained from a nontarget lesion or archival tissue. Bone biopsies should not be submitted. - Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 7 days of treatment initiation. - Has adequate organ function. - Has a life expectancy of at least 3 months. Exclusion Criteria: - Is unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan. - Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years with the following exceptions: Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers. - Participants with history of VHL disease (germline VHL mutation documented by a local test report or with clinical diagnosis) will be permitted provided concurrent lesions (other than the tumor type being assessed such as PPGL for Cohort A1 and pNET for Cohort A2) are localized without immediate need for intervention. Cohort D participants with VHL disease will not be eligible. - Prior history of surgical resection(s) for concurrent localized VHL disease-associated tumors is allowed provided there is no history of metastatic disease from concurrent tumors; history of systemic therapy for concurrent tumors will be exclusionary. - Participants with history of other genetic syndromes (such as those with succinate dehydrogenase subunit genes (SDHx) germline mutation or multiple endocrine neoplasia/MEN) will be allowed provided concurrent tumors (outside of the organ affected in Cohort A1, Cohort A2, C and D respectively) are localized and do not require immediate intervention; history of metastatic disease in concurrent tumors or history of systemic therapy for concurrent tumors will be exclusionary. - Cohort B1 participants with concomitant central nervous system (CNS) hemangioblastoma must not require immediate surgery or intervention and must not be at risk of imminent neurological complications. - Cohort B1 participants with concomitant retinal angiomas/retinal hemangioblastomas must not require immediate intervention. - Cohort B1 participants with any concomitant tumors must not require immediate surgery or intervention. - For Cohort B1 participants, history of any anticancer systemic therapy (including investigational agents) for any VHL disease-associated tumor or history of metastatic disease from any VHL disease-associated tumor or other non-VHL disease-related tumor(s) will be exclusionary. - Has known CNS metastases and/or carcinomatous meningitis. - Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or percutaneous transluminal coronary angioplasty (PTCA) =6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Concurrent uncontrolled hypertension defined as blood pressure >150/90 mm mercury (Hg) despite optimal antihypertensive medications within 2 weeks prior to the first dose of study treatment. Note: Medically controlled arrhythmia stable on medication is permitted. - Has any of the following: A pulse oximeter reading <92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen. - Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study. - Has had major surgery =4 weeks prior to first dose of study intervention. - Has received prior treatment (except somatostatin analogs for pNET participants) with chemotherapy, targeted therapy, biologics or other investigational therapy within the past 4 weeks of first dose of study intervention. - Has received prior locoregional therapies or radiation within the past 4 weeks of first dose of study intervention. - Has received prior treatment with Peptide Receptor Radionuclide Therapy (PRRT)/radionuclide therapy (such as 177Lu-Dotatate) or other radiopharmaceutical therapy within the past 12 weeks from Screening for participants with pNET. - Has received meta-iodobenzylguanidine (MIBG) therapy or other radiopharmaceutical therapy within the past 12 weeks from Screening for participants with PPGL. - Has received prior treatment with any HIF-2a inhibitor (including belzutifan). - Has a known hypersensitivity to the study treatment and/or any of its excipients. - Has toxicities from prior locoregional or systemic or any other therapies that is not recovered to Common Terminology Criteria for Adverse Events (CTCAE) =Grade 1 (with the exception of alopecia). - Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), or recombinant Erythropoietin (EPO) =28 days prior to the first dose of study intervention. - Is currently receiving strong inhibitors of Cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study. - Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study. - Is currently enrolled in and receiving study therapy, was enrolled in a study of an investigational agent, and received study therapy or used an investigational device within 4 weeks (28 days) of the first dose of study intervention. - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV) infection. - Has a known history of hepatitis B or known active hepatitis C (HCV) infection. - For Cohort A2, has a tumor histology consistent with poorly differentiated pNET, neuroendocrine carcinoma, or neuroendocrine tumor (NET) of nonpancreatic origin. 1. Poorly differentiated or high grade pancreatic pNET or pancreatic neuroendocrine carcinoma; mixed adenoneuroendocrine carcinoma of the pancreas or concurrent pancreatic ductal adenocarcinoma will not be allowed. 2. Neuroendocrine tumor of nonpancreatic origin such as gastrointestinal, lung/thoracic, unknown primary, or other organs (including adenocarcinoid/goblet cell carcinoid/small cell carcinoma/large cell carcinoma). Note: Neuroendocrine carcinoma of any origin is exclusionary. - For Cohort A2, participants who have uncontrolled symptoms from functional pNETs at study entry. - Has had an allogenic tissue/solid organ transplant. - For Cohort B1 participants, metastatic disease identified at Screening. - For Cohort C and GIST participants, clinically significant active bleeding (such as gastrointestinal [GI] bleeding), perforation, obstruction, and other disease-related complications, requiring emergency surgery. - For Cohort D participants, VHL disease is exclusionary.

Study Design


Intervention

Drug:
Belzutifan
Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.

Locations

Country Name City State
Australia The Royal Melbourne Hospital ( Site 1602) Parkville Victoria
Australia Prince of Wales Hospital-Medical Oncology ( Site 1601) Randwick New South Wales
Canada Tom Baker Cancer Center ( Site 0203) Calgary Alberta
Canada Princess Margaret Cancer Centre ( Site 0202) Toronto Ontario
China Peking University First Hospital-Urology ( Site 1900) Beijing Beijing
China West China Hospital of Sichuan University ( Site 1906) Cheng Du Sichuan
China Sun Yat-sen University Cancer Center ( Site 1905) Guangzhou Guangdong
China Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1904) Shanghai Shanghai
Denmark Rigshospitalet ( Site 0304) Copenhagen Hovedstaden
Denmark Rigshospitalet-Department of Endocrinology ( Site 0303) Copenhagen Hovedstaden
Denmark Odense Universitetshospital ( Site 0302) Odense Syddanmark
France Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0407) Le Kremlin-Bicêtre Paris
France Hôpital Edouard Herriot-oncologie ( Site 0405) Lyon Rhone-Alpes
France Institut Paoli-Calmettes-Oncology ( Site 0406) Marseille Bouches-du-Rhone
France Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0404) Paris
France CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402) Strasbourg Alsace
France Gustave Roussy ( Site 0403) Villejuif Ile-de-France
Germany Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism ( Site Berlin
Germany Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 0505) Düsseldorf Nordrhein-Westfalen
Germany Universitaetsklinikum Freiburg ( Site 0504) Freiburg Baden-Wurttemberg
Germany Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Department of Internal Medicine IV, Division ( München Bayern
Germany Comprehensive Cancer Center Mainfranken-Div. of Endocrinology and Diabetes ( Site 0500) Würzburg Bayern
Hungary Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály ( Site 0600) Budapest
Israel Sheba Medical Center-Institute of Endocrinology, Diabetes and Metabolism ( Site 1400) Ramat Gan
Israel Sourasky Medical Center ( Site 1401) Tel Aviv
Italy Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0701) Brescia
Italy Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroe Milano
Italy Ospedale San Raffaele-Oncologia Medica ( Site 0705) Milano Lombardia
Italy University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704) Naples Campania
Italy Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 0703) Verona
Japan National Cancer Center Hospital ( Site 1802) Chuo-ku Tokyo
Japan Kyoto University Hospital ( Site 1806) Kyoto
Japan Kochi Medical School Hospital ( Site 1807) Nankoku Kochi
Japan Hokkaido University Hospital ( Site 1800) Sapporo Hokkaido
Japan Tokyo Women's Medical University Adachi Medical Center ( Site 1803) Tokyo
Japan Yokohama City University Hospital-Department of Urology ( Site 1804) Yokohama Kanagawa
Netherlands Universitair Medisch Centrum Utrecht ( Site 1530) Utrecht
Russian Federation Endocrinology Research Center of Rosmedtechnologies-Surgery ( Site 0809) Moscow Moskva
Russian Federation Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 0801) Moscow Moskva
Russian Federation Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov ( Saint Petersburg Leningradskaya Oblast
Russian Federation Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 0803) Saint Petersburg Leningradskaya Oblast
Russian Federation GBUZ Republican Clinical Oncological Dispensary ( Site 0804) Ufa Baskortostan, Respublika
Singapore National Cancer Centre Singapore ( Site 1700) Singapore Central Singapore
Spain Hospital Universitari Vall d'Hebron ( Site 1100) Barcelona
Spain Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1103) Madrid Madrid, Comunidad De
Spain MD Anderson Cancer Center-Oncology ( Site 1102) Madrid Madrid, Comunidad De
Spain Hospital Universitario Central de Asturias-Medical Oncology ( Site 1101) Oviedo Asturias
Sweden Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 1204) Gothenburg Vastra Gotalands Lan
Sweden Skanes University Hospital Lund ( Site 1200) Lund Skane Lan
Sweden Karolinska Universitetssjukhuset Solna ( Site 1202) Stockholm Stockholms Lan
Sweden Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1201) Uppsala Uppsala Lan
Turkey Ankara Bilkent Sehir Hastanesi. ( Site 0904) Ankara
Turkey Hacettepe Universitesi-oncology hospital ( Site 0901) Ankara
Turkey Ege University Medicine of Faculty ( Site 0900) Bornova Izmir
Turkey Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 0902) Istanbul
United Kingdom Addenbrooke's Hospital ( Site 1309) Cambridge Cambridgeshire
United Kingdom The Beatson West of Scotland Cancer Centre ( Site 1308) Glasgow Glasgow City
United Kingdom Hammersmith Hospital-Medical Oncology ( Site 1304) London London, City Of
United Kingdom Royal Free Hospital ( Site 1302) London England
United States University of Michigan ( Site 0126) Ann Arbor Michigan
United States Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site Baltimore Maryland
United States National Institutes of Health ( Site 0125) Bethesda Maryland
United States Massachusetts General Hospital ( Site 0111) Boston Massachusetts
United States University of Texas MD Anderson Cancer Center ( Site 0112) Houston Texas
United States University of Iowa ( Site 0104) Iowa City Iowa
United States Cedars-Sinai Medical Center ( Site 0110) Los Angeles California
United States Vanderbilt University Medical Center ( Site 0107) Nashville Tennessee
United States Icahn School of Medicine at Mount Sinai ( Site 0123) New York New York
United States Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127) Philadelphia Pennsylvania
United States Washington University-Internal Medicine/Oncology ( Site 0124) Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Canada,  China,  Denmark,  France,  Germany,  Hungary,  Israel,  Italy,  Japan,  Netherlands,  Russian Federation,  Singapore,  Spain,  Sweden,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) ORR is the percentage of participants with complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD, at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression) or death due to any cause, whichever occurs first. Up to approximately 5.5 years
Secondary Duration of Response (DOR) as Assessed by BICR DOR is the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Up to approximately 5.5 years
Secondary Time to Response (TTR) as Assessed by BICR TTR is defined as the time from first dose of belzutifan to first documented evidence of CR or PR. Up to approximately 5.5 years
Secondary Disease Control Rate (DCR) as Assessed by BICR Disease control is a confirmed CR, PR, or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study). Up to approximately 5.5 years
Secondary Progressive Free Survival (PFS) as Assessed by BICR PFS is the time from first dose of belzutifan to the first documented PD or death from any cause, whichever occurs first. Up to approximately 5.5 years
Secondary Overall Survival (OS) OS is the time from first dose of belzutifan until death from any cause. Up to approximately 5.5 years
Secondary Number of Participants Experiencing Adverse Events (AEs) An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Up to approximately 5.5 years
Secondary Number of Participants Discontinuing Study Drug due to an AE An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinue study treatment due to an AE will be presented. Up to approximately 5.5 years
Secondary Time to Surgery (TTS) TTS is defined as the time from the first dose of belzutifan to the first documented surgical intervention or tumor reduction procedure. Up to approximately 5.5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05566093 - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors N/A
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Recruiting NCT05568017 - Neoadjuvant PRRT With Y-90-DOTATOC in pNET Phase 2
Not yet recruiting NCT06024343 - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction N/A
Recruiting NCT03891784 - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Phase 2
Recruiting NCT03204019 - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Recruiting NCT05997056 - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Phase 2
Not yet recruiting NCT06158516 - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Phase 2
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Recruiting NCT05040360 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00576680 - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05610826 - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Phase 1/Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2
Completed NCT03967951 - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT03435770 - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms N/A
Recruiting NCT04134832 - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting NCT05554744 - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors N/A
Completed NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1